Stockreport

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results [Yahoo! Finance]

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dose reached Monalizumab PACIFIC-9 on track to deliver data in H2 2026 [Read more]